
The panelists discussed how to differentiate Bruton tyrosine kinase (BTK) inhibitors when selecting treatment for chronic lymphocytic leukemia (CLL), beginning with mechanism.
In this OncLive News Network program, the panelists discussed the treatment landscape in chronic lymphocytic leukemia (CLL), including recent regulatory approvals and emerging strategies across frontline and relapsed/refractory disease. They compared covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, weighed fixed-duration against continuous therapy, and considered when triplet regimens justify added toxicity. The panelists assessed the selective role of frontline pirtobrutinib and shared approaches to managing cardiovascular comorbidities, anticoagulation, and common adverse events. In relapsed disease, they reviewed venetoclax-based therapy and retreatment, the choice between pirtobrutinib and venetoclax after covalent BTK inhibitor progression, adding pirtobrutinib to venetoclax-rituximab, and pirtobrutinib bridging to chimeric antigen receptor T-cell therapy. They emphasized that sequencing no longer follows a single algorithm and that disease biology, comorbidities, logistics, and patient preference should guide the best feasible frontline regimen. The panelists closed by identifying knowledge gaps, including therapy after frontline pirtobrutinib, comparative BTK inhibitor data, and emerging sonrotoclax combinations.

The panelists discussed how to differentiate Bruton tyrosine kinase (BTK) inhibitors when selecting treatment for chronic lymphocytic leukemia (CLL), beginning with mechanism.

The panelists discussed how they individualize frontline treatment for chronic lymphocytic leukemia (CLL) now that fixed-duration and continuous regimens both hold strong guideline support.

The panelists discussed triplet regimens combining a Bruton tyrosine kinase (BTK) inhibitor, venetoclax, and obinutuzumab for chronic lymphocytic leukemia (CLL), noting higher rates of undetectable measurable residual disease than with doublets.

The panelists discussed how safety profiles influence Bruton tyrosine kinase (BTK) inhibitor selection for patients with chronic lymphocytic leukemia (CLL) and cardiovascular disease, emphasizing the absence of head-to-head comparisons among acalabrutinib, zanubrutinib, and pirtobrutinib.

The panelists discussed the role of venetoclax-based therapy in relapsed chronic lymphocytic leukemia (CLL), including venetoclax-rituximab as a time-limited standard supported by long-term survival data, while noting that few patients in its pivotal trial had received a prior Bruton tyrosine kinase (BTK) inhibitor.

The panelists discussed chimeric antigen receptor (CAR) T-cell therapy for patients with chronic lymphocytic leukemia (CLL) who have failed both covalent Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

The panelists discussed why treatment sequencing in chronic lymphocytic leukemia (CLL) no longer follows a single algorithm now that Bruton tyrosine kinase (BTK) inhibitors and venetoclax are available alone or together in the frontline setting.